CLINICAL TRIALS

Guideline Number: CDG.006.15  Effective Date: May 1, 2020

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVERAGE RATIONALE</td>
<td>1</td>
</tr>
<tr>
<td>DOCUMENTATION REQUIREMENTS</td>
<td>3</td>
</tr>
<tr>
<td>DEFINITIONS</td>
<td>3</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>4</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>5</td>
</tr>
<tr>
<td>GUIDELINE HISTORY/REVISION INFORMATION</td>
<td>5</td>
</tr>
<tr>
<td>INSTRUCTIONS FOR USE</td>
<td>5</td>
</tr>
</tbody>
</table>

COVERAGE RATIONALE

Indications for Coverage

Effective for plan years starting on or after January 1, 2014, the Patient Protection and Affordable Care Act ("PPACA") requires non-grandfathered health plans to cover “Routine Patient Costs” incurred by a “Qualifying Individual” who is participating in an “Approved Clinical Trial.” Benefits include the reasonable and necessary items and services used to prevent, diagnose and treat complications arising from participation in a qualifying clinical trial. Benefits are available only when the Covered Person is clinically eligible for participation in the qualifying clinical trial as defined by the researcher.

I. Approved Clinical Trial

A. An “Approved Clinical Trial” is defined as:
   1. Phase I, Phase II, Phase III, or Phase IV clinical trial;
   2. Being conducted in relation to the prevention, detection or treatment for Cancer or other life threatening disease or condition; and
   3. Meets the requirements under Section II below.

For purposes of this benefit, a “life-threatening disease or condition” is one from which the likelihood of death is probable unless the course of the disease or condition is interrupted.

B. Additional Clinical Trials:

Coverage of Routine Patient Costs incurred by members participating in the following types of Clinical Trials is not currently mandated by PPACA. However, UnitedHealthcare’s standard Clinical Trial benefit would also include coverage of the Routine Patient Costs when a member is participating in a:

1. Phase I, Phase II or Phase III clinical trial;
2. Being conducted in relation to the detection or treatment of non-life threatening:
   a. Cardiovascular disease (cardiac/stroke);
   b. Surgical musculoskeletal disorders of the spine, hip and knees; and/or
   c. Other Clinical Trials: Certain plans may allow Clinical Trials relating to other diseases or disorders which are not life-threatening.

3. Meets the requirements under Section II below.

II. Criteria For Approved Clinical Trials

A. The Clinical Trial must be described in paragraph 1, 2 or 3 below.

1. The study or investigation is approved or funded (which may include funding through in-kind contributions) by one or more of the following:
   a. National Institutes of Health (NIH) [includes National Cancer Institute (NCI)]
   b. Centers for Disease Control and Prevention (CDC)
   c. Agency for Healthcare Research and Quality (AHRQ)
   d. Centers for Medicare and Medicaid Services (CMS)
   e. A cooperative group or center of any of the entities described above or the Department of Defense (DOD) or the Veterans Administration (VA)
   f. A qualified non-governmental research entity identified in the guidelines issued by the National Institutes of Health for center support grants
III. Qualified Individual
A. A qualified individual must be:
   1. Covered under the health plan; and
   2. Eligible to participate in an approved clinical trial according to the trial protocol when the individual:
      a. Was referred to the clinical trial by an in-network health care professional who has concluded that the individual's participation would be appropriate because the individual is eligible for the trial according to its protocol; or
      b. Provides the plan with medical and scientific information that establishes that participation would be appropriate because the individual is eligible for the trial according to its protocol.

B. Additional Requirements:
   1. The clinical trial must have a written protocol that describes a scientifically sound study that has been approved by all relevant institutional review boards (IRBs) before participants are enrolled in the trial. We may, at any time, request documentation about the trial.
   2. The subject or purpose of the trial must be the evaluation of an item or service that meets the definition of a Covered Care Health Service and is not otherwise excluded under the Policy.

IV. Routine Patient Costs During Clinical Trials Include Covered Health Care Services:
A. For which Benefits are typically provided absent a clinical trial.
B. Required solely for:
   1. The provision of the Experimental or Investigational Service(s) or item (e.g., the infusion administration services to deliver an investigational drug); and/or
   2. The clinically appropriate monitoring of the effects of the service or item (e.g., lab tests and imaging done at a frequency consistent with signs and symptoms and other standards of care for that diagnosis or treatment type); and/or
   3. The prevention of complications.
C. Needed for reasonable and necessary care arising from the provision of an Experimental or Investigational Service(s) or item.

Network Plans
If one or more network providers are participating in a clinical trial, then UnitedHealthcare may require that the Qualified Individual participate in the clinical trial using a network provider, as long as the network provider will accept the qualifying individual as a participant in the trial. However, if an Approved Clinical Trial is conducted outside of the Qualified Individual’s state of residence, then UnitedHealthcare may not deny or otherwise limit payment for Routine Patient Services solely on the basis that the trial is conducted out-of-state.

Coverage Limitations and Exclusions
Benefits for Clinical Trials do not include:
- The Experimental or Investigational Service(s) or item that is used in the clinical trial is not covered, except for the following:
  - Certain Category B Devices
  - Certain promising interventions for members with terminal illnesses
  - Other items and services that, in our determination, meet specified criteria in accordance with our medical and drug policies
- Items and services provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the member. Examples include, but are not limited to:
  - Laboratory tests and imaging studies done at a frequency dictated by the study protocol and not consistent with signs and symptoms and other standards of care for that diagnosis or treatment type
  - A service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis
  - Items and services provided by the research sponsors free of charge for any person enrolled in the trial
• Travel and transportation expenses are excluded from coverage. These include, but are not limited to:
  o Fees for all types of transportation (Examples include, but are not limited to: personal vehicle, taxi, medical
    van, ambulance, commercial airline, and train)
  o Rental car expenses
  o Mileage reimbursement for driving a personal vehicle
  o Lodging
  o Meals
• Routine patient costs obtained out-of-Network where non-network benefits do not exist under the plan.
• Clinical Trials that do not meet the requirements listed in the Indications for Coverage section above. An example
  includes, but is not limited to, Phase 0 drug Clinical Trials.

**DOCUMENTATION REQUIREMENTS**

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws
that may require coverage for a specific service. The documentation requirements outlined below are used to assess
whether the member meets the clinical criteria for coverage but do not guarantee coverage of the service requested.

<table>
<thead>
<tr>
<th>HCPCS Codes*</th>
<th>Required Clinical Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials</td>
<td>• Provider should call the number on the member's ID card to verify what clinical information is required for review</td>
</tr>
</tbody>
</table>

*For code descriptions, see the Applicable Codes section.

**DEFINITIONS**

The following definitions may not apply to all plans. Refer to the member specific benefit plan document for applicable
definitions.

**Category B Devices**: As determined by the FDA, non-experimental and/or investigational devices where the
incremental risk is the primary risk in question (i.e., underlying questions of safety and effectiveness of that device
type have been resolved), or it is known that the device type can be safe and effective because, for example, other
manufacturers have obtained FDA approval for that device type. Only certain FDA-designated Category B Devices are
covered. In order to be covered, all of the following criteria must be met:
• The device must be used within the context of an FDA-approved clinical trial.
• The device must be used according to the clinical trial's approved protocols.
• Must fall under a covered benefit category and must not be excluded by law, regulation or current Medicare
  coverage guidelines.
• The device is medically necessary for the member, and the amount, duration and frequency of use or application
  of the service is medically appropriate.
• The device is furnished in a setting appropriate to the member's medical needs and condition.

**Clinical Trials/Studies Involving Investigational New Drugs**: (National Institutes of Health)
(https://clinicaltrials.gov/ct2/about-studies/home – About Clinical Studies > Glossary of Common Site Terms > P)
• **Phase 0**: Exploratory study involving very limited human exposure to the drug, with no therapeutic or diagnostic
goals (for example, screening studies, microdose studies).
• **Phase 1**: Studies that are usually conducted with healthy volunteers and that emphasize safety. The goal is to
  find out what the drug's most frequent and serious adverse events are and, often, how the drug is metabolized and
  excreted.
• **Phase 2**: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a
  certain disease or condition). For example, participants receiving the drug may be compared with similar
  participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug.
  Safety continues to be evaluated, and short-term adverse events are studied.
• **Phase 3**: Studies that gather more information about safety and effectiveness by studying different populations
  and different dosages and by using the drug in combination with other drugs.
• **Phase 4**: Studies occurring after the US Food and Drug Administration (FDA) has approved a drug for marketing.
  These include post-market requirement and commitment studies that are required of or agreed to by the sponsor.
  These studies gather additional information about a drug's safety, efficacy, or optimal use.

**Covered Health Care Service(s)**: Health care services, including supplies or Pharmaceutical Products, which we
determine to be all of the following:
• Provided for the purpose of preventing, evaluating, diagnosing or treating a Sickness, Injury, Mental Illness,
  substance-related and addictive disorders, condition, disease or its symptoms.
• Medically Necessary.
• Described as a Covered Health Care Service in the Certificate under Section 1: Covered Health Care Services and in the Schedule of Benefits.
• Not excluded in the Certificate under Section 2: Exclusions and Limitations.

Exceptions:
• Clinical Trials for which Benefits are available as described under Clinical Trials in Section 1: Covered Health Care Services.
• If you are not a participant in a qualifying clinical trial, as described under Clinical Trials in Section 1: Covered Health Care Services, and have a Sickness or condition that is likely to cause death within one year of the request for treatment we may, as we determine, consider an otherwise Experimental or Investigational Service to be a Covered Health Care Service for that Sickness or condition. Prior to such a consideration, we must first establish that there is sufficient evidence to conclude that, albeit unproven, the service has significant potential as an effective treatment for that Sickness or condition.

Experimental or Investigational Service(s): Medical, surgical, diagnostic, psychiatric, mental health, substance-related and addictive disorders or other health care services, technologies, supplies, treatments, procedures, drug therapies, medications or devices that, at the time we make a determination regarding coverage in a particular case, are determined to be any of the following:
• Not approved by the U.S. Food and Drug Administration (FDA) to be lawfully marketed for the proposed use and not identified in the American Hospital Formulary Service or the United States Pharmacopoeia Dispensing Information as appropriate for the proposed use.
• Subject to review and approval by any institutional review board for the proposed use. (Devices which are FDA approved under the Humanitarian Use Device exemption are not Experimental or Investigational.)
• The subject of an ongoing clinical trial that meets the definition of a Phase I, II or III clinical trial set forth in the FDA regulations, regardless of whether the trial is actually subject to FDA oversight.

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-Covered Health Care Service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

Coding Clarification: Clinical Trials claims are not limited to these modifiers. However, if a claim has one of these modifiers it is considered to be a Clinical Trials claim.

<table>
<thead>
<tr>
<th>Modifier Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q0</td>
<td>Investigational clinical service provided in a clinical research study that is in an approved clinical research study</td>
</tr>
<tr>
<td>Q1</td>
<td>Routine clinical service provided in a clinical research study that is in an approved clinical research study</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G0276</td>
<td>Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial</td>
</tr>
<tr>
<td>G0293</td>
<td>Noncovered surgical procedure(s) using conscious sedation, regional, general, or spinal anesthesia in a Medicare qualifying clinical trial, per day</td>
</tr>
<tr>
<td>G0294</td>
<td>Noncovered procedure(s) using either no anesthesia or local anesthesia only, in a Medicare qualifying clinical trial, per day</td>
</tr>
<tr>
<td>G2000</td>
<td>Blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ECT, current covered gold standard) or magnetic seizure therapy (MST, noncovered experimental therapy), performed in an approved IDE-based clinical trial, per treatment session</td>
</tr>
<tr>
<td>S9988</td>
<td>Services provided as part of a Phase I clinical trial</td>
</tr>
<tr>
<td>S9990</td>
<td>Services provided as part of a Phase II clinical trial</td>
</tr>
<tr>
<td>HCPCS Code</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>S9991</td>
<td>Services provided as part of a Phase III clinical trial</td>
</tr>
</tbody>
</table>

**Not Covered**

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S9992</td>
<td>Transportation costs to and from trial location and local transportation costs (e.g., fares for taxicab or bus) for clinical trial participant and one caregiver/companion</td>
</tr>
<tr>
<td>S9994</td>
<td>Lodging costs (e.g., hotel charges) for clinical trial participant and one caregiver/companion</td>
</tr>
<tr>
<td>S9996</td>
<td>Meals for clinical trial participant and one caregiver/companion</td>
</tr>
</tbody>
</table>

**Coding Clarification:** Clinical Trials claims are not limited to this diagnosis code. However, if a claim has this code it is considered to be a Clinical Trials claim.

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z00.6</td>
<td>Encounter for examination for normal comparison and control in clinical research program</td>
</tr>
</tbody>
</table>

**REFERENCES**


**GUIDELINE HISTORY/REVISION INFORMATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
</table>
| 05/01/2020 | • Routine review; no change to coverage guidelines  
|            | • Archived previous policy version CDG.006.14 |

**INSTRUCTIONS FOR USE**

This Coverage Determination Guideline provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this guideline, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Coverage Determination Guideline is provided for informational purposes. It does not constitute medical advice.

This Coverage Determination Guideline may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R126CIM.pdf)).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Coverage Determination Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

For self-funded plans with SPD language other than fully-insured Generic COC language, please refer to the member specific benefit plan document for coverage.